PRACA PRZEGLĄDOWA
Musculoskeletal involvement in systemic sclerosis
1
Department of Rheumatology, Systemic Connective Tissue Diseases and Internal Diseases, Medical University of Lublin, Poland
2
Department of Rheumatology and Systemic Connective Tissue Diseases, Independent Public Hospital No. 4 in Lublin, Poland
Data nadesłania: 21-04-2024
Data ostatniej rewizji: 22-06-2024
Data akceptacji: 28-06-2024
Data publikacji online: 18-08-2024
Data publikacji: 16-08-2024
Autor do korespondencji
Ewa Wielosz
Ewa Wielosz, Department of Rheumatology, Systemic Connective Tissue Diseases and Internal Diseases, Medical University of Lublin, 8 Jaczewskiego St., 20-954 Lublin, Poland, e-mail: ewa.wielosz@wp.pl
Ewa Wielosz, Department of Rheumatology, Systemic Connective Tissue Diseases and Internal Diseases, Medical University of Lublin, 8 Jaczewskiego St., 20-954 Lublin, Poland, e-mail: ewa.wielosz@wp.pl
SŁOWA KLUCZOWE
DZIEDZINY
Twardzina układowa, myositis i powiązane zespoły - etiologia, patogeneza, obraz kliniczny i leczenie
STRESZCZENIE
Systemic sclerosis (SSc) is a multi-organ, systemic connective tissue disease, which affects the lungs, heart, gastrointestinal tract, kidneys, skin, and musculoskeletal system. Musculoskeletal involvement is observed in 40–90% of patients with SSc. During the disease, any structure of the musculoskeletal system, such as bones, joints, tendon sheaths, tendons, and muscles, may be affected. The most common symptoms include joint pain, arthritis, tendinitis leading to tendon rupture, acro-osteolysis, calcinosis, myalgia, and myositis. Osteo-articular complications and changes in the soft tissues of the hand lead to finger contracture, which causes deterioration of the patients’ quality of life and disability. To sum up, a more detailed understanding of the aetiology leading to progressive changes in the musculoskeletal system may contribute to the introduction of new therapeutic options, and thus improve the quality of life and reduce disability in patients with SSc.
REFERENCJE (52)
1.
Kayser C, Victória de Oliveira Martins L. Treatment of inflammatory arthritis in systemic sclerosis. Rheum Dis Clin North Am 2023; 49: 337–343, DOI: 10.1016/j.rdc.2023.01.008.
2.
Lorand V, Chirjak L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med 2014; 43: 315–328, DOI: 10.1016/j.lpm.2014.03.027.
3.
Blank R, Nwawka O, Yusov A, Gordon J. Inflammatory arthritis in systemic sclerosis. What to do? J Scleroderma Related Disord 2019; 4: 3–16, DOI: 10.1177/2397198318779532.
4.
Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev 2017; 16: 774–786; DOI: 10.1016/j.autrev.2017.05.024.
5.
Corallo C, Franci B, Lucani B, et al. From microvasculature to fibroblasts: contribution of anti-endothelial cell antibodies in systemic sclerosis. Int J Immunopathol Pharmacol 2015; 28: 93–103, DOI: 10.1177/0394632015572750.
6.
Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, et al. Systemic sclerosis pathogenesis and emerging therapies, beyond the fibroblast. Biomed Res Int 2019; 2019: 4569826, DOI: 10.1155/2019/4569826.
7.
Balbach ML, Corty R, Hill B, et al. Development of a musculoskeletal ultrasound protocol to evaluate hand pain in systemic sclerosis patients. Diagnostics 2024; 14: 669, DOI: 10.3390/diagnostics14070669.
8.
Azarbani N, Javadzadeh A, Mohseni I, et al. Association of musculoskeletal and radiological features with clinical and serological findings in systemic sclerosis: a single-centre registry study. Mediterr J Rheumatol 2020; 31: 341–349, DOI: 10.31138/mjr.31.3.341.
9.
Mouthon L. Hand involvement in systemic sclerosis. Presse Med 2013; 42: 1616–1626, DOI: 10.1016/j.lpm.2013.10.003.
10.
Arslan Tas D, Erken E, Sakalli H, Yucel AE. Evaluating hand in systemic sclerosis. Rheumatol Int 2012; 32: 3581–3586, DOI: 10.1007/s00296-011-2205-3.
11.
Sandler RD, Matucci-Cernic M, Hughes M. Musculoskeletal hand involvement in systemic sclerosis. Semin Arthritis Rheum 2020; 50: 329–334, DOI: 10.1016/j.semarthrit.2019.11.003.
12.
La Montagna G, Sodano A, Capurro V, et al. The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol 2005; 34: 35–41, DOI: 10.1007/s00256-004-0830-6.
13.
Bassel M, Hudson M, Taillefer SS, et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762–767, DOI: 10.1093/rheumatology/keq310.
14.
Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis 1982; 41: 147–152, DOI: 10.1136/ard.41.2.147.
15.
Varju C, Pentek M, Lorand V, et al. Musculoskeletal involvement in systemic sclerosis: an unexplored aspect of the disease. J Scleroderma and Related Dis 2017; 2: 19–32, DOI: 10.1136/ard.41.2.147.
16.
Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65: 1088–1092, DOI: 10.1136/ard.2005.044602.
17.
Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease sub-sets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185–1192, DOI: 10.1093/rheumatology/ken179.
18.
Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010; 37: 1488–1501, DOI: 10.3899/jrheum.091165.
19.
Bálint Z, Farkas H, Farkas N, et al. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol 2014; 32: 68–74.
20.
Ingegnoli F, Boracchi P, Ambrogi F, et al. Hand impairment in systemic sclerosis: association of different hand indices with organ involvement. Scand J Rheumatol 2010; 39: 393–397, DOI: 10.3109/03009741003629028.
21.
Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016; 75: 103–109, DOI: 10.1136/annrheumdis-2014-205295.
22.
Elhai M, Guerini H, Bazeli R, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res (Hoboken) 2012; 64: 1244–1249, DOI: 10.1002/acr.21668.
23.
Cuomo G, Zappia M, Abignano G, et al. Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1414–1417, DOI: 10.1093/rheumatology/kep250.
24.
Fairchild R, Horomanski A, Sharpless L, et al. Ultrasound evaluation of the hands and wrists in patients with systemic sclerosis: osteophytosis is a major contributor to tender joints. Semin Arthritis Rheum 2021; 51: 735–740.
25.
Hubac J, Gilson M, Gaudin P, et al. Ultrasound prevalence of wrist, hand, ankle and foot synovitis and tenosynovitis in systemic sclerosis, and relationship with disease features and hand disability. Joint Bone Spine 2020; 87: 229–233, DOI: 10.1016/j.jbspin.2020.01.011.
26.
Low AH, Lax M, Johnson SR, Lee P. Magnetic resonance imaging of the hand in systemic sclerosis. J Rheumatol 2009; 36: 961–964, DOI: 10.3899/jrheum.080795.
27.
Chitale S, Ciapetti A, Hodgson R, et al. Magnetic resonance imaging and musculoskeletal ultrasonography detect and characterize covert inflammatory arthropathy in systemic sclerosis patients with arthralgia. Rheumatology (Oxford) 2010; 49: 2357–2361, DOI: 10.1093/rheumatology/keq268.
28.
Abdel-Magied RA, Lotfi A, AbdelGawad EA. Magnetic resonance imaging versus musculoskeletal ultrasonography in detecting inflammatory arthropathy in systemic sclerosis patients with hand arthralgia. Rheumatol Int 2013; 33: 1961–1966, DOI: 10.1007/s00296-013-2665-8.
29.
Erre GL, Marongiu A, Fenu P, et al. The “sclerodermic hand”: a radiological and clinical study. Joint Bone Spine 2008; 75: 426–431, DOI: 10.1016/j.jbspin.2007.07.017.
30.
Muraru S, Mihai C, Elhai M, et al. Arthritis in patients with very early systemic sclerosis: a comprehensive clinical and prognostic analysis. Rheumatology (Oxford) 2024: keae247, DOI: 10.1093/rheumatology/keae247.
31.
Kamalaksha S, White DHN, Solanki KK. Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis. Int J Rheum Dis 2018; 21: 1430–1435, DOI: 10.1111/1756-185X.13330.
32.
Ueda-Hayakawa I, Hasegawa M, Kumada S, et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 2010; 49: 2135–2139, DOI: 10.1093/rheumatology/keq205.
33.
Wielosz E, Majdan M, Dryglewska M, Zwolak R. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: prevalence and relationships with joint manifestations. Adv Clin Exp Med 2018; 27: 1253–1257, DOI: 10.17219/acem/69921.
34.
Avouac J, Mogavero G, Guerini H, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis 2011; 70: 630–633, DOI: 10.1136/ard.2010.134304.
35.
Laustriat G, Ruyssen-Witrand A, Constantin A, et al. Anti-citrullinated peptides antibodies in systemic sclerosis: meta-analysis of frequency and meaning. Joint Bone Spine 2018; 85: 147–153, DOI: 10.1016/j.jbspin.2017.11.006.
36.
Terenzi R, Karalilova R, Lepri G, et al. Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. Rheumatology (Oxford) 2020; 59: 580–585, DOI: 10.1093/rheumatology/kez322.
37.
Young A, Namas R, Dodge C, Khanna D. Hand impairment in systemic sclerosis: various manifestations and currently available treatment. Curr Treatm Opt Rheumatol 2016; 2: 252–269, DOI: 10.1007/s40674-016-0052-9.
38.
Clements P. Management of musculoskeletal involvement in systemic sclerosis. Curr Treatm Opt Rheumatol 2016; 2: 61–68, DOI: 10.1007/s40674-016-0039-6.
39.
Stoenoiu MS, Houssiau FA, Lecouvet FE. Tendon friction rubs in systemic sclerosis: a possible explanation – an ultrasound and magnetic resonance imaging study. Rheumatology (Oxford) 2013; 52: 529–533, DOI: 10.1093/rheumatology/kes307.
40.
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet 2023; 401: 304–318, DOI: 10.1016/S0140-6736(22)01692-0.
41.
Fourmond S, Parreau S, Dumonteil S, et al. The functional disabilities of the dominant and opposite hands in patients with systemic sclerosis. Clin Exp Rheumatol 2024, DOI: 10.55563/clinexprheumatol/db7upl.
42.
Erol K, Gok K, Cengiz G, Ozgocmen S. Hand functions in systemic sclerosis and rheumatoid arthritis and influence on clinical variables. Int J Rheum Dis 2018; 21: 249–252, DOI: 10.1111/1756-185X.13044.
43.
Nagy G, Dobrota R, Becker MO, et al. Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis. Arthritis Res Ther 2023; 25: 84, DOI: 10.1186/s13075-023-03063-1.
44.
Sakata K, Kaneko Y, Yasuoka H, Takeuchi T. Association of radiographic findings in hand X-ray with clinical features and autoantibodies in patients with systemic sclerosis. Clin Rheumatol 2020; 39: 113–118, DOI: 10.1007/s10067-019-04639-6.
45.
Badiee F, Fatemi A, Zahedpasha R, et al. Hands and feet radiologic involvements in systemic sclerosis. BMC Rheumatol 2023; 7: 9, DOI: 10.1186/s41927-023-00336-9.
46.
Davuluri S, Lood C, Chung L. Calcinosis in systemic sclerosis. Curr Opin Rheumatol 2022; 34: 319–327, DOI: 10.1097/BOR.0000000000000896.
47.
Bratoiu I, Burlui AM, Cardoneanu A, et al. The involvement of smooth muscle, striated muscle, and the myocardium in scleroderma: a review. Int J Mol Sci 2022; 23: 12011, DOI: 10.3390/ijms231912011.
48.
Ranque B, Bérezné A, Le-Guern V, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol 2010; 39: 498–505, DOI: 10.3109/03009741003774626.
49.
Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 2018; 70: 1820–1828, DOI: 10.1002/art.40560.
50.
Cheng H, Yu Z, Yan CL, et al. Long-term efficacy and low adverse events of methylprednisolone pulses combined to low-dose glucocorticoids for systemic sclerosis: a retrospective clinical study of 10 years’ follow-up. J Inflamm Res 2022; 15: 4421–4433, DOI: 10.2147/JIR.S373387.
51.
Akram Q, Roberts M, Oddis C, et al. Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease. Reumatologia 2016; 54: 35–37, DOI: 10.5114/reum.2016.58760.
52.
Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 2015; 42: 236–242, DOI: 10.3899/jrheum.140833.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
